Selective serotonin reuptake inhibitors and the risk of bleeding

Selective serotonin reuptake inhibitors and risk of cerebral bleeding.

S elective serotonin reuptake inhibitors (SSRIs) are used commonly to treat poststroke depression. They are also being evaluated in clinical trials for their effectiveness in facilitating functional recovery after stroke. 3,4 However, observational studies suggest that SSRIs are associated with several adverse outcomes in older people (aged >65 years), including an increased risk of all-cause m...

Selective Serotonin Reuptake Inhibitors

It has long been postulated that a deficiency in CNS serotonergic activity is the cause of, or a predisposing factor for, depression. [1] However, the evidence for this association is largely circumstantial and it certainly does not represent an adequate and full model for depression, probably due to there being multiple aetiological factors. [2] Some pharmacological trial data also cast doubt ...

Selective serotonin reuptake inhibitors.

The risk of suicidality with selective serotonin reuptake inhibitors.

Antidepressants are efficacious in the treatment of depression but they are not without side effects. The recent findings on the risk of suicide with selective serotonin reuptake inhibitor treatment, however, have raised serious concerns about the risk-benefit ratio of their use. The development of the concerns is traced and the risks discussed, particularly in the child and adolescent group. T...

Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins.

BACKGROUND Treatment with vitamin K antagonists (coumarins) is associated with an increased risk of bleeding. Because use of selective serotonin reuptake inhibitors (SSRIs) is also associated with an increased risk of bleeding, we assessed the odds ratio (OR) of abnormal bleeding associated with SSRI use in users of the coumarins acenocoumarol or phenprocoumon and compared this with the OR of b...